UCB's Bimekizumab Shows Sustained Efficacy Against HS Abscesses, Tunnels, and Pain Over 3 Years

BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Reduction of draining tunnels sustained to three years: Of patients who had at least one draining tunnel at baseline, 48.2% had none at one year, and 62.9% at three years* – indicating sustained symptom relief in these lesionsZero draining tunnel…

bimekizumab data shows sustained benefits in hidradenitis suppurativa

Three-year trial results reveal long-term improvements in pain and lesion resolution

UCB's Bimekizumab Shows Sustained Efficacy Against HS Abscesses, Tunnels, and Pain Over 3 Years

UCB reveals three-year data on bimekizumab, showcasing significant pain relief and lesion resolution in hidradenitis suppurativa patients at the 2025 SHSA.